Jacolien van der Marel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacolien van der Marel has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre E Voskuyl
Department of Rheumatology, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
1 shared publication - Anne A. Schouffoer
Department of Rheumatology, Leiden University Medical Center, PO BOX 9600, 2300 RC, Leiden, The Netherlands
1 shared publication - Annemie Jm Schuerwegh
16Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
1 shared publication - Diana W. Bianchi
Section On Prenatal Genomics and Fetal Therapy, Center for Precision Health Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, USA
1 shared publication - Linda van Wyk
Leiden University Medical Center, Leiden, The Netherlands
1 shared publication - Sicco A Scherjon
Department of Obstetrics, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, PO BOX 9600, 2300 RC Leiden, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 4 November 2011
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 13 (6) , R183
Increased incidence of pregnancy complications in women who later develop scleroderma: a case control study
Introduction: Studies have shown that fetal progenitor cells persist in maternal blood or bone marrow for more than 30 years after delivery. Increased trafficking of fetal cells occurs during pregnancy complications, such as hypertension, preeclampsia, miscarriage and intra-uterine growth restriction (IUGR). Women with these pregnancy complications are significantly more often HLA-class II compatible with their spouses. Women who later develop scleroderma also give birth to an HLA-class II child more often. From these prior studies we hypothesized that preeclampsia and other pregnancy complications could be associated with increased levels of fetal cell trafficking, and later be involved in the development of scleroderma. Methods: This study was a retrospective multi-centre matched case-control study. One-hundred-and-three women with systemic sclerosis (SSc) and 103 women with no history of SSc or other autoimmune disease were given a questionnaire regarding complications during pregnancy, such as hypertension, intra-uterine growth restriction (IUGR) and miscarriage. Conditional logistic regression analysis was used to assess associations. Results: We found a statistically significantly increased incidence of having had a pregnancy history of hypertension or a fetus with IUGR in women who subsequently developed SSc compared to healthy controls. We found an odds ratio of 2.6 (95% confidence interval (CI): 1.1 to 4.6) for hypertensive complications during pregnancy and an odds ratio of 3.9 (95% CI: 1.2 to 12.3) for intra-uterine growth restriction for women with SSc compared to healthy controls. Conclusions: This is the first study to show an association between hypertensive complications during pregnancy or IUGR and the development of SSc at a later age. We speculate that the pregnancy abnormalities may have resulted in increased fetomaternal trafficking, which may have played a role in the increased incidence of SSc. Further studies are indicated to examine this putative relationship.
- 4 November 2011
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 13 (6) , R183
Open AccessIncreased incidence of pregnancy complications in women who later develop scleroderma: a case control study
Introduction: Studies have shown that fetal progenitor cells persist in maternal blood or bone marrow for more than 30 years after delivery. Increased trafficking of fetal cells occurs during pregnancy complications, such as hypertension, preeclampsia, miscarriage and intra-uterine growth restriction (IUGR). Women with these pregnancy complications are significantly more often HLA-class II compatible with their spouses. Women who later develop scleroderma also give birth to an HLA-class II child more often. From these prior studies we hypothesized that preeclampsia and other pregnancy complications could be associated with increased levels of fetal cell trafficking, and later be involved in the development of scleroderma. Methods: This study was a retrospective multi-centre matched case-control study. One-hundred-and-three women with systemic sclerosis (SSc) and 103 women with no history of SSc or other autoimmune disease were given a questionnaire regarding complications during pregnancy, such as hypertension, intra-uterine growth restriction (IUGR) and miscarriage. Conditional logistic regression analysis was used to assess associations. Results: We found a statistically significantly increased incidence of having had a pregnancy history of hypertension or a fetus with IUGR in women who subsequently developed SSc compared to healthy controls. We found an odds ratio of 2.6 (95% confidence interval (CI): 1.1 to 4.6) for hypertensive complications during pregnancy and an odds ratio of 3.9 (95% CI: 1.2 to 12.3) for intra-uterine growth restriction for women with SSc compared to healthy controls. Conclusions: This is the first study to show an association between hypertensive complications during pregnancy or IUGR and the development of SSc at a later age. We speculate that the pregnancy abnormalities may have resulted in increased fetomaternal trafficking, which may have played a role in the increased incidence of SSc. Further studies are indicated to examine this putative relationship.